Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Mortality and Survival Rates in Secondary AML
Cancer; ePub 2017 Apr 7; Boddu, Kantarjian, et al
Lower intensity treatments were linked with decreased early mortality rates and better overall survival in patients with secondary acute myeloid leukemia (s-AML), according to a study involving nearly 1,000 individuals.
Newly diagnosed participants received 1 of the following 5 treatments:
- High- or intermediate-dose cytarabine-based intensive chemotherapy (IC).
- Hypomethylating agents (HMAs).
- Low-dose cytarabine (LDAC) combination.
- CPX-351.
- Investigational agents.
Among the results:
- Complete remission rate was 36% in patients receiving HMAs.
- This rate in those receiving IC, CPX-351, or LDACs ranged between 43% and 46%.
- HMAs and LDACs produced a median overall survival rate of nearly 7 months, a month and a half longer than more intensive regimens.
- 1 in every 10 receiving less intensive therapy proceeded to transplantation, vs only 4.3% of IC patients.
- Survival in those receiving either CPX-351 or lower intensity treatments was similar.
- Age >70 years, adverse karyotype, and a prior hematological disorder were linked with decreased overall survival.
Citation:
Boddu P, Kantarjian H, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. [Published online ahead of print April 7, 2017]. Cancer. doi:10.1002/cncr.30704.